Clinical trials: Phase I
Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
Background: Human papilloma virus (HPV) is a common sexually transmitted disease. There are more than 100 different HPV types, and both males and females can get HPV infection.
- Conditions
- Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
- Trial name
- NCT00798265
- Testing
- Gardasil, Survey
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV…
- Trial name
- NCT02309892
- Testing
- L-DOS47
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Helix BioPharma Corporation
Exocrine Pancreatic Insufficiency
Phase 1 Study to Assess Safety and Efficacy of ANG003
Randomized, parallel, active-treatment Phase 1 study of a single dose of orally administered ANG003 with a test meal in adult subjects with cystic fibrosis-related exocrine pancreatic insufficiency.
- Trial name
- NCT06052293
- Testing
- ANG003
- Where
- 20 sites in United States
- Volunteers
- 57 people
- Sponsor
- Anagram Therapeutics, Inc.
Brain and Central Nervous System Tumors
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- RTOG 0913 (NCT01062399)
- Testing
- concurrent RAD001 10 mg/day, concurrent temozolomide, Radiation therapy
- Where
- 36 sites in United States, Canada and 1 more
- Volunteers
- 279 people
- Sponsor
- Radiation Therapy Oncology Group
Lyme Disease
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
- Trial name
- NCT05975099
- Testing
- mRNA-1975, mRNA-1982
- Where
- 20 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Small Cell Lung Cancer
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
This study will test the safety of the study drug, DS-3201b, given in combination with irinotecan to people who have recurrent small cell lung cancer (SCLC).
- Trial name
- NCT03879798
- Testing
- DS-3201b, irinotecan
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Substance Use Disorders
Woebot for Substance Use Disorders
Phase 1 of this study aims to develop a digitally-delivered substance use disorder program through the Woebot app-based platform (W-SUDs) and evaluate the effectiveness of, patient satisfaction with and the acceptability of…
- Trial name
- NCT04096001
- Testing
- Woebot-SUDs (W-SUDs)
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Woebot Health
HIV
Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring
This prospective, randomized, single-blinded, placebo controlled trial will examine the safety and pharmacokinetics (PK) of a polyurethane tenofovir disoproxil fumarate (TDF) vaginal ring when used continuously for 14 consecutive…
- Trial name
- TDF IVR-001 (NCT02006264)
- Testing
- TDF Intravaginal Ring
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer
RATIONALE: Pyridoxine (vitamin B6) and topical urea/lactic acid-based cream may prevent or lessen hand-foot syndrome caused by chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00296036
- Testing
- pyridoxine hydrochloride, urea/lactic acid-based topical cream
- Where
- 231 sites in United States
- Volunteers
- 137 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neuroblastoma, Osteosarcoma
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
The purpose of this study is to test the safety of a study drug called humanized 3F8 bispecific antibody (Hu3F8-BsAb).
- Conditions
- Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers
- Trial name
- NCT03860207
- Testing
- Humanized 3F8 Bispecific Antibody, Blood draw
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Y-mAbs Therapeutics
Acute Myelogenous Leukemia
Epigenetic Reprogramming in Relapse/Refractory AML
This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
- Trial name
- NCT03263936
- Testing
- Decitabine, Vorinostat, Filgrastim (G-CSF)
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 37 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Sickle Cell Disease
A Safety Study of Eptifibatide in Patients With Sickle Cell Disease
This study will evaluate the safety of eptifibatide in sickle cell patients and how well it works during the course of painful crises.
- Trial name
- NCT00834899
- Testing
- Eptifibatide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of North Carolina, Chapel Hill
Colorectal Neoplasms
A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
This was a Phase 1, open-label, single-center study of CS-1008, an immunoglobulin G subclass 1 (IgG1) humanized monoclonal antibody, in subjects with advanced colorectal carcinoma who had received ≥ 1 prior chemotherapy regimen…
- Trial name
- NCT01220999
- Testing
- CS-1008
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Ludwig Institute for Cancer Research
Plasmacytoma, Recurrent Multiple Myeloma
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or…
- Conditions
- Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT03031730
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
Letrozole is an aromatase inhibitor that is approved in the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.
- Trial name
- NCT00634634
- Testing
- Sorafenib, Letrozole
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Rutgers, The State University of New Jersey
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
This is a global, open-label, multi-arm, parallel multi-cohort, multi-center, Phase 1/2 study to determine the safety, tolerability, PK, efficacy and patient-reported quality of life of JCAR017 in combination with various agents.
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
- Trial name
- PLATFORM (NCT03310619)
- Testing
- JCAR017, Durvalumab, CC-122
- Where
- 9 sites in United States
- Volunteers
- 62 people
- Sponsor
- Celgene
Prostatic Neoplasm
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
The purpose of this study is to evaluate a short course (five radiation treatments) of very focused ("stereotactic") external beam radiation therapy for the treatment of early stage prostate cancer.
- Trial name
- NCT01540994
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sharp HealthCare
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
This phase I/II trial is studying the side effects and best dose of bendamustine hydrochloride when given together with carboplatin, etoposide, and rituximab in treating patients with diffuse large B cell lymphoma or Hodgkin…
- Trial name
- TREC (NCT01165112)
- Testing
- Bendamustine Hydrochloride, Carboplatin, Rituximab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Washington
Asthma
A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma
To evaluate the PK profile of a single-dose of 140 mg subcutaneous (SC) administration of MEDI9929 (AMG 157) in adolescent subjects with mild to moderate asthma.
- Trial name
- NCT02512900
- Testing
- MEDI9929, 140 mg
- Where
- 4 sites in Poland
- Volunteers
- 21 people
- Sponsor
- MedImmune LLC
Colorectal Cancer, Colon Cancer
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
This study has two portions. The main goal of the Phase I portion of this research study is to see what doses of CB-839 and capecitabine can safely be given to patients without having too many side effects.
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer, Solid Tumor
- Trial name
- NCT02861300
- Testing
- CB-839, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- David Bajor, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.